Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Alimentary Pharmacology & Therapeutics"" wg kryterium: JN


Tytuł:
Editorial: treat-to-target in ulcerative colitis clinical management-a small price to pay? Authors' reply.
Autorzy:
Cortesi PA; Research Centre on Public Health (CESP), University of Milano-Bicocca, Monza, Italy.
Fiorino G; Department of Gastroenterology and Digestive Endoscopy, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy.
Mantovani LG; Research Centre on Public Health (CESP), University of Milano-Bicocca, Monza, Italy.; IRCCS, Istituto Auxologico Italiano, Milan, Italy.
Danese S; Department of Gastroenterology and Digestive Endoscopy, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Mar; Vol. 57 (5), pp. 571-572.
Typ publikacji:
Editorial; Comment
MeSH Terms:
Colitis, Ulcerative*/drug therapy
Humans
Opinia redakcyjna
Tytuł:
Editorial: let's get physical-long-term benefits of vigorous physical activity in patients with nonalcoholic fatty liver disease.
Autorzy:
Heinle JW; Division of Gastroenterology and Hepatology, Department of Medicine, The Pennsylvania State University- Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
Stine JG; Division of Gastroenterology and Hepatology, Department of Medicine, The Pennsylvania State University- Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.; Liver Center, The Pennsylvania State University- Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.; Department of Public Health Sciences, The Pennsylvania State University- College of Medicine, Hershey, Pennsylvania, USA.; Cancer Institute, The Pennsylvania State University- Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Mar; Vol. 57 (6), pp. 729-730.
Typ publikacji:
Editorial; Research Support, N.I.H., Extramural; Comment
MeSH Terms:
Non-alcoholic Fatty Liver Disease*
Humans ; Exercise
Raport
Tytuł:
Editorial: definition of factors associated with poor quality of life in patients with IBS-but where to from here? Authors' reply.
Autorzy:
Goodoory VC; Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.; Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.
Guthrie EA; Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
Ng CE; County Durham and Darlington NHS Foundation Trust, Durham, UK.
Black CJ; Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.; Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.
Ford AC; Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.; Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Mar; Vol. 57 (6), pp. 725-726.
Typ publikacji:
Editorial; Comment
MeSH Terms:
Irritable Bowel Syndrome*
Humans ; Quality of Life
Opinia redakcyjna
Tytuł:
Editorial: faecal microbiota transplantation for recurrent C. difficile infections-getting the support that is needed.
Autorzy:
Chauhan A; Northern Health, Melbourne, Victoria, Australia.
Garg M; Northern Health, Melbourne, Victoria, Australia.; Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Mar; Vol. 57 (5), pp. 585-586.
Typ publikacji:
Editorial; Research Support, Non-U.S. Gov't; Comment
MeSH Terms:
Clostridioides difficile*
Clostridium Infections*/therapy
Humans ; Fecal Microbiota Transplantation ; Feces
Raport
Tytuł:
Letter: improved alanine aminotransferase level in non-cirrhotic and low-viral load chronic hepatitis B patients treated with nucleotide/nucleoside analogues -authors' reply.
Autorzy:
Huang R; Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.; Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, Jiangsu, China.
Wang J; Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.; Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, Jiangsu, China.
Yan X; Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Zhu C; Department of Infectious Diseases, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, Jiangsu, China.
Wu C; Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.; Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, Jiangsu, China.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Mar; Vol. 57 (5), pp. 589-590.
Typ publikacji:
Letter
MeSH Terms:
Hepatitis B, Chronic*/drug therapy
Humans ; Nucleosides/therapeutic use ; Nucleotides/therapeutic use ; Alanine Transaminase ; Viral Load ; Antiviral Agents/therapeutic use ; Hepatitis B virus/genetics ; DNA, Viral ; Hepatitis B e Antigens
Opinia redakcyjna
Tytuł:
Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin.
Autorzy:
Zeng RW; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Yong JN; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Tan DJH; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Fu CE; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Lim WH; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Xiao J; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Chan KE; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Tan C; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Goh XL; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Chee D; Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore.
Syn N; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Tan EX; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore.; National University Centre for Organ Transplantation, National University Health System, Singapore, Singapore.
Muthiah MD; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore.; National University Centre for Organ Transplantation, National University Health System, Singapore, Singapore.
Ng CH; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Tamaki N; Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
Lee SW; Division of Gastroenterology and Hepatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.; The Catholic University Liver Research Centre, Seoul, Korea.
Kim BK; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.; Yonsei Liver Center, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea.
Nguyen MH; Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA.
Loomba R; NAFLD Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California at San Diego, San Diego, California, USA.
Huang DQ; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore.; National University Centre for Organ Transplantation, National University Health System, Singapore, Singapore.; NAFLD Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California at San Diego, San Diego, California, USA.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Mar; Vol. 57 (6), pp. 600-609. Date of Electronic Publication: 2023 Jan 10.
Typ publikacji:
Meta-Analysis; Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use
Liver Neoplasms*/drug therapy
Metformin*
Humans ; Aspirin/therapeutic use ; Chemoprevention
Czasopismo naukowe
Tytuł:
Editorial: definition of factors associated with poor quality of life in patients with IBS-but where to from here?
Autorzy:
Thwaites PA; Department of Gastroenterology, Central Clinical School, Monash University, Melbourne, Australia.; Alfred Health, Melbourne, Australia.
Burgell RE; Department of Gastroenterology, Central Clinical School, Monash University, Melbourne, Australia.; Alfred Health, Melbourne, Australia.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Mar; Vol. 57 (6), pp. 723-724.
Typ publikacji:
Editorial; Research Support, Non-U.S. Gov't; Comment
MeSH Terms:
Irritable Bowel Syndrome*/complications
Humans ; Quality of Life ; Surveys and Questionnaires ; Anxiety
Raport
Tytuł:
Letter: improved alanine aminotransferase level in patients with chronic hepatitis B without cirrhosis and low viral load treated with nucleotide/nucleoside analogues.
Autorzy:
Jang TY; Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.; Department of Internal Medicine, Pingtung Hospital, Ministry of Health and Welfare, Ping-Tung, Taiwan.; Department of Occupational and Environmental Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Mar; Vol. 57 (5), pp. 587-588.
Typ publikacji:
Letter; Comment
MeSH Terms:
Hepatitis B, Chronic*/drug therapy
Humans ; Nucleosides/therapeutic use ; Alanine Transaminase ; Nucleotides/therapeutic use ; Viral Load ; Liver Cirrhosis/drug therapy ; Hepatitis B virus/genetics ; DNA, Viral ; Antiviral Agents/therapeutic use ; Hepatitis B e Antigens
Opinia redakcyjna
Tytuł:
Editorial: moving from the clinic towards population hepatology-authors' reply.
Autorzy:
Hagström H; Division of Hepatology, Department of Upper GI, Karolinska University Hospital, Stockholm, Sweden.; Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
Hammar N; Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Mar; Vol. 57 (6), pp. 728.
Typ publikacji:
Editorial; Comment
Opinia redakcyjna
Tytuł:
Editorial: inflammatory bowel disease and sleep.
Autorzy:
Horsfall E; Department of Gastroenterology, Palmerston North Hospital, Manawatu, New Zealand.
Irwin J; Department of Gastroenterology, Palmerston North Hospital, Manawatu, New Zealand.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Mar; Vol. 57 (5), pp. 573-574.
Typ publikacji:
Letter; Comment
MeSH Terms:
Inflammatory Bowel Diseases*
Humans ; Sleep
Opinia redakcyjna
Tytuł:
Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials.
Autorzy:
Peyrin-Biroulet L; Department of Gastroenterology, University of Lorraine, CHRU-Nancy, Nancy, France.; University of Lorraine, Inserm, NGERE, Nancy, France.
Ghosh S; APC Microbiome Ireland, University College Cork, Cork, Ireland.
Lee SD; University of Washington, Seattle, Washington, USA.
Lee WJ; AbbVie Inc., North Chicago, Illinois, USA.
Griffith J; AbbVie Inc., North Chicago, Illinois, USA.
Wallace K; AbbVie Inc., North Chicago, Illinois, USA.
Berg S; AbbVie Inc., North Chicago, Illinois, USA.
Liao X; AbbVie Inc., North Chicago, Illinois, USA.
Panes J; Hospital Clínic Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
Loftus EV Jr; Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
Louis E; University Hospital CHU of Liège, Liège, Belgium.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Mar; Vol. 57 (5), pp. 496-508. Date of Electronic Publication: 2022 Oct 20.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Crohn Disease*/drug therapy
Crohn Disease*/chemically induced
Inflammatory Bowel Diseases*/drug therapy
Humans ; Quality of Life ; Antibodies, Monoclonal/adverse effects ; Fatigue/chemically induced ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Meta-analysis: Efficacy and safety of albumin in the prevention and treatment of complications in patients with cirrhosis.
Autorzy:
Leache L; Unit of Innovation and Organization, Navarre Health Service, Pamplona, Navarre, Spain.; Navarre Institute for Health Research (IdiSNA), Pamplona, Navarre, Spain.
Gutiérrez-Valencia M; Unit of Innovation and Organization, Navarre Health Service, Pamplona, Navarre, Spain.; Navarre Institute for Health Research (IdiSNA), Pamplona, Navarre, Spain.
Saiz LC; Unit of Innovation and Organization, Navarre Health Service, Pamplona, Navarre, Spain.; Navarre Institute for Health Research (IdiSNA), Pamplona, Navarre, Spain.
Uriz J; Department of Gastroenterology and Hepatology, University Hospital of Navarre, Pamplona, Spain.
Bolado F; Department of Gastroenterology and Hepatology, University Hospital of Navarre, Pamplona, Spain.
García-Erce JA; Navarra's Blood and Tissue Bank, Navarre Health Service, Pamplona, Spain.; Grupo Español de Rehabilitación Multimodal (GERM), Aragon Health Science Institute, PBM Group, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
Cantarelli L; Department of Hospital Pharmacy, University Hospital of Canary Islands (CHUC), Santa Cruz de Tenerife, Spain.
Erviti J; Unit of Innovation and Organization, Navarre Health Service, Pamplona, Navarre, Spain.; Navarre Institute for Health Research (IdiSNA), Pamplona, Navarre, Spain.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Mar; Vol. 57 (6), pp. 620-634. Date of Electronic Publication: 2022 Dec 15.
Typ publikacji:
Systematic Review; Journal Article; Review
MeSH Terms:
Liver Transplantation*
Hepatic Encephalopathy*/complications
Peritonitis*/complications
Humans ; Liver Cirrhosis/complications ; Quality of Life ; Paracentesis ; Albumins
Czasopismo naukowe
Tytuł:
Editorial: considerations for expanding treatment in grey zone chronic hepatitis B patients.
Autorzy:
Liu YC; College of Medicine, Chang Gung University, Taipei, Taiwan.; Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou medical center, Taoyuan, Taiwan.
Jeng WJ; College of Medicine, Chang Gung University, Taipei, Taiwan.; Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou medical center, Taoyuan, Taiwan.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Mar; Vol. 57 (5), pp. 577-578.
Typ publikacji:
Editorial; Research Support, Non-U.S. Gov't; Comment
MeSH Terms:
Hepatitis B, Chronic*/drug therapy
Humans ; Hepatitis B Surface Antigens ; Antiviral Agents/therapeutic use
Raport
Tytuł:
Editorial: real-world evidence of tofacitinib and vedolizumab in ulcerative colitis-are we one step closer to better positioning therapies after anti-TNF failure? Authors' reply.
Autorzy:
Buisson A; Université Clermont Auvergne, Inserm, CHU Clermont-Ferrand, 3iHP, Service d'Hépato-Gastro Entérologie, Clermont-Ferrand, France.; Université Clermont Auvergne, 3iHP, Inserm U1071, M2iSH, USC-INRA 2018, Clermont-Ferrand, France.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Mar; Vol. 57 (6), pp. 735-736.
Typ publikacji:
Editorial; Comment
MeSH Terms:
Colitis, Ulcerative*
Humans ; Tumor Necrosis Factor Inhibitors ; Antibodies, Monoclonal, Humanized
Opinia redakcyjna
Tytuł:
Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in patients with inflammatory bowel disease.
Autorzy:
Richard N; Department of Gastroenterology, CHU Rouen, Rouen, France.; University of Rouen Normandie, INSERM, ADEN UMR 1073, Nutrition, Inflammation and Microbiota-Gut-Brain Axis, Rouen, France.
Vuitton L; Department of Gastroenterology, Besançon University Hospital, Besançon, France.
Fumery M; Department of Gastroenterology, Amiens University Hospital, Amiens, France.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Mar; Vol. 57 (6), pp. 741-742.
Typ publikacji:
Letter; Comment
MeSH Terms:
Inflammatory Bowel Diseases*/drug therapy
Colitis, Ulcerative*/drug therapy
Humans ; Antibodies, Monoclonal, Humanized/therapeutic use ; Administration, Intravenous ; Gastrointestinal Agents/therapeutic use ; Treatment Outcome
Opinia redakcyjna
Tytuł:
Editorial: baseline hepatitis B virus haplotype number may help predict a functional cure in patients with chronic hepatitis B treated with nucleotide analogues.
Autorzy:
Li YJ; Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China.
Chen EQ; Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Mar; Vol. 57 (5), pp. 581-582.
Typ publikacji:
Editorial; Comment
MeSH Terms:
Hepatitis B virus*/genetics
Hepatitis B, Chronic*/drug therapy
Hepatitis B, Chronic*/genetics
Humans ; Nucleotides/therapeutic use ; Haplotypes ; Antiviral Agents/therapeutic use ; Hepatitis B Surface Antigens
Opinia redakcyjna
Tytuł:
Letter: sleep duration and the incidence of inflammatory bowel disease.
Autorzy:
Chang HC; Library, Chung Shan Medical University Hospital, Taichung, Taiwan.; Evidence-Based Medicine Center, Chung Shan Medical University Hospital, Taichung, Taiwan.; School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Gau SY; School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Mar; Vol. 57 (5), pp. 595-596.
Typ publikacji:
Letter; Comment
MeSH Terms:
Sleep Duration*
Inflammatory Bowel Diseases*/epidemiology
Humans ; Incidence ; Sleep
Opinia redakcyjna
Tytuł:
Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg-positive chronic hepatitis B.
Autorzy:
Wagner J; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.; Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia.
Yuen L; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.; Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Littlejohn M; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Sozzi V; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Jackson K; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Martin R; Gilead Sciences, Foster City, California, USA.
Aeschbacher T; Gilead Sciences, Foster City, California, USA.
Suri V; Gilead Sciences, Foster City, California, USA.
Tan SK; Gilead Sciences, Foster City, California, USA.
Feierbach B; Gilead Sciences, Foster City, California, USA.
Gaggar A; Gilead Sciences, Foster City, California, USA.
Marcellin P; Hôpital Beaujon, University of Paris, Clichy, France.
Buti Ferret M; Liver Unit, Valle d'Hebron (Ciberehd) University Hospital, Barcelona, Spain.
Janssen HLA; Toronto Center for Liver Diseases, Toronto General Hospital, University: Health Network, University of Toronto, Toronto, Ontario, Canada.
Gane E; New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand.
Meagher N; Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Price DJ; Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.
Wong D; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.; Department of Gastroenterology, St. Vincent's Hospital, Melbourne, Victoria, Australia.
Thompson AT; Department of Gastroenterology, St. Vincent's Hospital, Melbourne, Victoria, Australia.
Revill PA; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.; Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Mar; Vol. 57 (5), pp. 509-523. Date of Electronic Publication: 2022 Nov 25.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hepatitis B, Chronic*/diagnosis
Hepatitis B, Chronic*/drug therapy
Hepatitis B, Chronic*/genetics
Hepatitis C, Chronic*/drug therapy
Humans ; Hepatitis B virus/genetics ; Hepatitis B e Antigens/genetics ; Hepatitis B Surface Antigens/genetics ; Antiviral Agents/therapeutic use ; Haplotypes ; Tenofovir/therapeutic use ; Genotype ; DNA, Viral/genetics ; DNA, Viral/analysis
Czasopismo naukowe
Tytuł:
Faecal microbiota transplantation for recurrent C. difficile infections: challenges and improvement opportunities for clinical practice and healthcare systems.
Autorzy:
Hocking L; RAND Europe, Cambridge, UK.
Ianiro G; Gastroenterology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
Leong RW; Macquarie University Hospital and Concord Hospital, Sydney, Australia.
Iqbal T; University of Birmingham, Birmingham, UK.
Kao D; University of Alberta, Edmonton, Alberta, Canada.
Cabling M; RAND Europe, Cambridge, UK.
Stockwell S; RAND Europe, Cambridge, UK.
Romanelli RJ; RAND Europe, Cambridge, UK.
Marjanovic S; RAND Europe, Cambridge, UK.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Mar; Vol. 57 (5), pp. 549-564. Date of Electronic Publication: 2022 Dec 10.
Typ publikacji:
Review; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Clostridioides difficile*
Clostridium Infections*/therapy
Humans ; Fecal Microbiota Transplantation/methods ; Feces ; Treatment Outcome ; Delivery of Health Care ; Recurrence
Czasopismo naukowe
Tytuł:
Editorial: treat-to-target in ulcerative colitis clinical management-a small price to pay?
Autorzy:
Barber GE; Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA.
Gubatan J; Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Mar; Vol. 57 (5), pp. 569-570.
Typ publikacji:
Editorial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Comment
MeSH Terms:
Colitis, Ulcerative*/drug therapy
Humans
Raport

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies